#1 Clinical Trials Search in Europe

Mk-2060

MK-2060 is an investigational drug being developed to prevent thrombotic complications in patients with end-stage renal disease (ESRD) undergoing hemodialysis. This article summarizes recent clinical trials evaluating the safety, efficacy, and pharmacokinetics of MK-2060 in this patient population. The studies aim to determine optimal dosing and assess the drug’s potential for reducing arteriovenous graft thrombosis and other clotting issues in ESRD patients.

Table of Contents

What is MK-2060?

MK-2060 is a new drug being developed to help patients with end-stage renal disease (ESRD), also known as end-stage kidney disease or chronic kidney failure[1][2][3]. ESRD is a condition where the kidneys have stopped working well enough for a person to survive without dialysis or a kidney transplant. MK-2060 is specifically designed for patients who are receiving hemodialysis, a treatment that filters waste and excess fluid from the blood when the kidneys can no longer perform this function.

What Conditions Does MK-2060 Treat?

MK-2060 is primarily being studied for the following conditions:

  • End-Stage Renal Disease (ESRD): This is the main condition that MK-2060 aims to treat. ESRD patients often face complications related to blood clotting, which this drug may help prevent[1].
  • Arteriovenous Graft (AVG) Thrombosis: This is a specific complication in ESRD patients where blood clots form in the special blood vessel access created for hemodialysis. MK-2060 is being tested to see if it can prevent these clots from forming[3].

How Does MK-2060 Work?

MK-2060 is a type of drug called a monoclonal antibody. It works by targeting a specific protein in the blood called Factor XI[3]. Factor XI is involved in blood clotting. By blocking this protein, MK-2060 may help prevent harmful blood clots from forming, which is a common problem for patients on hemodialysis.

How is MK-2060 Administered?

MK-2060 is given through an intravenous (IV) infusion. This means it’s delivered directly into the bloodstream through a vein. The dosing schedule being studied typically involves:

  • A “loading dose” given every other day during the first week (usually 3 doses)
  • After the first week, doses are given once a week[3]

The exact dose and schedule may vary depending on the specific study and the patient’s needs.

Current Clinical Trials

MK-2060 is currently being studied in several clinical trials to determine its safety and effectiveness. These trials are looking at different aspects of the drug:

  • Safety and drug interactions: One study is examining how safe it is to use MK-2060 along with another common medication called clopidogrel[1].
  • Dosing and effects in older patients: Another study is focusing on how the drug works in older ESRD patients, looking at different doses and how the body processes the medication[2].
  • Preventing AVG thrombosis: A larger study is testing whether MK-2060 can effectively prevent blood clots in the dialysis access site and how safe it is for long-term use[3].

Safety and Side Effects

As with any new medication, researchers are carefully monitoring the safety of MK-2060. Some of the potential side effects being watched for include:

  • Bleeding events: Since MK-2060 affects blood clotting, there’s a potential for increased bleeding[1].
  • Injection site reactions: This could include pain, redness, or swelling where the IV is given[2].
  • Systemic reactions: These are effects that might occur throughout the body, such as fever or changes in blood pressure[2].

It’s important to note that not all patients will experience side effects, and the clinical trials are designed to carefully monitor and manage any that do occur.

Future Prospects for MK-2060

The development of MK-2060 represents an exciting potential advance in the care of ESRD patients on hemodialysis. If the clinical trials show positive results, this drug could offer several benefits:

  • Reduced risk of blood clots in dialysis access sites, which could help maintain the effectiveness of hemodialysis treatments
  • Potentially fewer complications related to blood clotting for ESRD patients
  • A new option for patients who may not be able to use current blood-thinning medications

However, it’s important to remember that MK-2060 is still in the testing phase. More research is needed to fully understand its benefits and risks before it can be approved for general use[3].

Aspect Details
Drug Name MK-2060
Drug Type Monoclonal antibody against Factor XI
Target Population Patients with End-Stage Renal Disease (ESRD) on hemodialysis
Administration Intravenous (IV) infusion
Primary Objective Prevention of thrombotic complications, particularly arteriovenous graft thrombosis
Key Outcomes Measured Safety, tolerability, pharmacokinetics, pharmacodynamics, time to first AVG thrombosis event
Safety Monitoring Adverse events, bleeding events, hemostasis time
Trial Phases Phase 2
Dosing Strategies Various, including loading doses followed by weekly maintenance doses
Comparator Placebo (normal saline)

FAQ

  • What is MK-2060? MK-2060 is an experimental monoclonal antibody that targets Factor XI, a protein involved in blood clotting. It is being developed to prevent thrombotic complications in patients with end-stage renal disease who are on hemodialysis.
  • How is MK-2060 administered? MK-2060 is administered via intravenous (IV) infusion. The dosing schedule varies depending on the study, but typically involves a loading dose followed by weekly maintenance doses.
  • What are the main goals of the MK-2060 clinical trials? The main goals are to evaluate the safety, tolerability, and efficacy of MK-2060 in preventing thrombotic events, particularly arteriovenous graft thrombosis. The trials also aim to determine the optimal dosing regimen and assess the drug's pharmacokinetics in ESRD patients.
  • What are the potential benefits of MK-2060 for ESRD patients? MK-2060 may help reduce the risk of blood clots and thrombotic complications in ESRD patients undergoing hemodialysis, potentially improving the longevity of vascular access sites and reducing associated complications.
  • What are the main safety concerns being evaluated in the MK-2060 trials? The trials are closely monitoring for adverse events, particularly bleeding-related events. They are also assessing the drug's impact on hemostasis (blood clotting) and its potential interactions with other medications commonly used in ESRD patients, such as clopidogrel.

Ongoing Clinical Trials on Mk-2060

  • Study on MK-2060 for Preventing Blood Clots in Dialysis Patients with End-Stage Kidney Disease

    Not recruiting

    1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Czechia Germany Greece Italy Portugal +2

Glossary

  • End-Stage Renal Disease (ESRD): A condition where the kidneys have permanently lost their ability to function, requiring ongoing dialysis or kidney transplantation for survival.
  • Hemodialysis: A treatment for kidney failure that uses a machine to filter waste and excess fluids from the blood when the kidneys can no longer perform this function.
  • Arteriovenous Graft (AVG): A surgically created connection between an artery and a vein, typically used to provide vascular access for hemodialysis.
  • Thrombosis: The formation of a blood clot inside a blood vessel, which can obstruct blood flow.
  • Factor XI: A protein involved in the blood clotting process, which is the target of the MK-2060 antibody.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific substances in the body, used in the treatment of various diseases.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of their actions.
  • Adverse Event (AE): Any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medical treatment or procedure.
  • Hemostasis: The process which causes bleeding to stop, involving the interaction of blood vessels, platelets, and clotting factors.

References

  1. https://clinicaltrials.gov/study/NCT05335005
  2. https://clinicaltrials.gov/study/NCT03873038
  3. https://clinicaltrials.gov/study/NCT05027074